AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
Publications Library
Please visit this section often to keep up to date on AFINITOR® published findings.
Register now for access to the most up-to-date AFINITOR news, clinical information, peer-to-peer events and more.
Next: Key Events
